Ocugen Reports Positive GA Trial Data, Extends Cash Runway
MALVERN, PA — Ocugen (NASDAQ: OCGN) reported positive mid-stage clinical data for its geographic atrophy gene therapy program while raising additional capital expected to fund operations into 2028 as the …
Ocugen Reports Positive GA Trial Data, Extends Cash Runway Read More